Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules

NCT: NCT07237373 · RECRUITING

NCT IDNCT07237373
StatusRECRUITING
Start Date2026-03-03
Completion2031-04-01

Brief Summary

The goal of this observational study is to learn if radiofrequency ablation (RFA), a minimally invasive thermoablation technique, can safely reduce symptoms and improve quality of life in adults with symptomatic benign thyroid nodules or autonomously functioning thyroid nodules. The main questions it aims to answer are: * Does RFA improve health-related quality of life (HRQoL) as measured by the ThyPRO-39 questionnaire? * Does RFA effectively reduce nodule volume and related symptoms (compressive or cosmetic)? Participants will: * Undergo a radiofrequency ablation procedure of the thyroid nodule performed under ultrasound guidance in an outpatient setting. * Complete quality of life questionnaires (ThyPRO-39) before treatment and at follow-up visits. Attend follow-up visits at 1, 3, 6, and 12 months with: * Ultrasound assessments of the thyroid nodule * Symptom and cosmetic scoring * Blood tests to monitor thyroid function * Safety checks for possible complications

Frequently Asked Questions

What is Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules?

Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules is a clinical trial registered under NCT07237373. Current status: RECRUITING.

What is the status of NCT07237373?

The current status of NCT07237373 (Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules) is: RECRUITING.

When did Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules start?

Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules started on 2026-03-03.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.